Presentation is loading. Please wait.

Presentation is loading. Please wait.

Figure 2 Disease-free survival in patients with normal versus high pretreatment C-reactive protein (CRP) levels. From: Elevated serum levels of C-reactive.

Published byLeona Carpenter Modified over 5 years ago

Similar presentations

Presentation on theme: "Figure 2 Disease-free survival in patients with normal versus high pretreatment C-reactive protein (CRP) levels. From: Elevated serum levels of C-reactive."— Presentation transcript:

1 Figure 2 Disease-free survival in patients with normal versus high pretreatment C-reactive protein (CRP) levels. From: Elevated serum levels of C-reactive protein are indicative of a poor prognosis in patients with esophageal cancer Dis Esophagus. 2005;18(3): doi: /j x Dis Esophagus | © 2005 International Life Sciences Institute

2 Figure 1 Overall survival in patients with normal versus high pretreatment C-reactive protein (CRP) levels. From: Elevated serum levels of C-reactive protein are indicative of a poor prognosis in patients with esophageal cancer Dis Esophagus. 2005;18(3): doi: /j x Dis Esophagus | © 2005 International Life Sciences Institute

Download ppt "Figure 2 Disease-free survival in patients with normal versus high pretreatment C-reactive protein (CRP) levels. From: Elevated serum levels of C-reactive."

Similar presentations

C - reactive protein. C - reactive protein ( CRP ) ◌ C-reactive protein was originally discovered as a substance in the serum of patients with acute inflammation.

C - reactive protein. C - reactive protein ( CRP ) ◌ C-reactive protein was originally discovered as a substance in the serum of patients with acute inflammation.
Combined PTEN Mutation and Protein Expression Associate with Overall and Disease- Free Survival of Glioblastoma Patients Jie Xu, Zhaoli Li, Jilin Wang,

Combined PTEN Mutation and Protein Expression Associate with Overall and Disease- Free Survival of Glioblastoma Patients Jie Xu, Zhaoli Li, Jilin Wang,
Fig. 1 Frequency distribution of initial palliative treatment modalities used. EBRT, external beam radiotherapy. Initial palliative treatment modality.

Fig. 1 Frequency distribution of initial palliative treatment modalities used. EBRT, external beam radiotherapy. Initial palliative treatment modality.
A Prognostic Scoring Model for the Utility of Induction Chemotherapy Prior to Neoadjuvant Chemoradiotherapy in Esophageal Cancer  Mian Xi, MD, Zhongxing.

A Prognostic Scoring Model for the Utility of Induction Chemotherapy Prior to Neoadjuvant Chemoradiotherapy in Esophageal Cancer  Mian Xi, MD, Zhongxing.
Measuring prognosis Patients want to know likely outcome

Measuring prognosis Patients want to know likely outcome
Thierry Delaunoit, Paul J. Limburg, Richard M. Goldberg, James F

Thierry Delaunoit, Paul J. Limburg, Richard M. Goldberg, James F
Potential Molecular Mechanisms for Improved Prognosis and Outcome with Neoadjuvant Chemotherapy Prior to Laparoscopical Radical Hysterectomy for Patients.

Potential Molecular Mechanisms for Improved Prognosis and Outcome with Neoadjuvant Chemotherapy Prior to Laparoscopical Radical Hysterectomy for Patients.
Novel Pretreatment Scoring Incorporating C-reactive Protein to Predict Overall Survival in Advanced Hepatocellular Carcinoma with Sorafenib Treatment Liver.

Novel Pretreatment Scoring Incorporating C-reactive Protein to Predict Overall Survival in Advanced Hepatocellular Carcinoma with Sorafenib Treatment Liver.
Fig. 1 Selection of patients

Fig. 1 Selection of patients
Mature Results from a Phase II Trial of Postoperative Concurrent Chemoradiotherapy for Poor Prognosis Cancer of the Esophagus and Gastroesophageal Junction 

Mature Results from a Phase II Trial of Postoperative Concurrent Chemoradiotherapy for Poor Prognosis Cancer of the Esophagus and Gastroesophageal Junction 
Fig. 1 Kaplan–Meier curves of post-progression survival (PPS) in the docetaxel and best supportive care (BSC) groups. Median PPS was 5.4 months in the.

Fig. 1 Kaplan–Meier curves of post-progression survival (PPS) in the docetaxel and best supportive care (BSC) groups. Median PPS was 5.4 months in the.
From: Esophageal motility disorders after gastric banding

From: Esophageal motility disorders after gastric banding
2epart EXTRAPULMONARY SMALL CELL CANCER OF THE ESOPHAGUS INTRODUCTION

2epart EXTRAPULMONARY SMALL CELL CANCER OF THE ESOPHAGUS INTRODUCTION
The Prognostic Value Of Dynamic Monitoring C-Reactive Protein (CRP) Serum Levels In NK/T-Cell Lymphoma by Bing Bai, Qi-chun Cai, Xiao-Xiao Wang, Qingqing.

The Prognostic Value Of Dynamic Monitoring C-Reactive Protein (CRP) Serum Levels In NK/T-Cell Lymphoma by Bing Bai, Qi-chun Cai, Xiao-Xiao Wang, Qingqing.
Perioperative versus Preoperative Chemotherapy with Surgery in Patients with Resectable Squamous Cell Carcinoma of Esophagus  Yang Zhao, MD, ZhiJun Dai,

Perioperative versus Preoperative Chemotherapy with Surgery in Patients with Resectable Squamous Cell Carcinoma of Esophagus  Yang Zhao, MD, ZhiJun Dai,
An evaluation of clinical stability criteria to predict hospital course in community-acquired pneumonia  A.R. Akram, J.D. Chalmers, J.K. Taylor, J. Rutherford,

An evaluation of clinical stability criteria to predict hospital course in community-acquired pneumonia  A.R. Akram, J.D. Chalmers, J.K. Taylor, J. Rutherford,
Volume 137, Issue 3, Pages (September 2009)

Volume 137, Issue 3, Pages (September 2009)
Survival of Patients With Superficial Esophageal Adenocarcinoma After Endoscopic Treatment vs Surgery  Saowanee Ngamruengphong, Herbert C. Wolfsen, Michael.

Survival of Patients With Superficial Esophageal Adenocarcinoma After Endoscopic Treatment vs Surgery  Saowanee Ngamruengphong, Herbert C. Wolfsen, Michael.
Kenneth Song, Samir Hanash  Gastroenterology 

Kenneth Song, Samir Hanash  Gastroenterology 
Figure 2 The association between CD8+ T‑cell density of the tumour

Figure 2 The association between CD8+ T‑cell density of the tumour

Similar presentations

Ads by Google